Weight Loss Reduces IMAT and Liver Fat Compared to Exercise: Implications for Muscle Quality and Metabolic Health.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 41622038.
- Also identified by DOI 10.1210/clinem/dgag018.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Weight loss improves insulin sensitivity and liver fat but reduces lean mass. Whether reductions in intermuscular adipose tissue (IMAT) exceed muscle loss and how these effects compare with endurance exercise training without weight loss remains unclear. In a 12-week randomized intervention, forty-six individuals with obesity were assigned to weight loss (WL - age 39.7±1.3; BMI 35.2±0.9; W/M 8/9), endurance exercise training without weight loss (EX - age 39.7±1.6; BMI 36.0±1.1; W/M 8/8), or delayed-control intervention groups (age 39.8±1.4; BMI 36.8±1.3; W/M 6/7). Changes in IMAT volume, skeletal muscle mass, and liver fat measured by MRI; insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp; and plasma lipidomics and metabolomics by LC-MS based methods. WL reduced body weight (-10.5%; p<0.001), liver steatosis (-33.1%; p<0.0001), and IMAT volume (-12.7%; p<0.0001), while improving insulin sensitivity (42%; p=0.004). IMAT decreased significantly more than skeletal muscle mass (-4.2%, p=0.17), indicating improved muscle quality. EX increased insulin sensitivity (23%; P=0.04) and VO₂peak (7.6%; p<0.001) but did not significantly change IMAT or liver fat. DXA overestimated muscle loss compared with MRI. WL decreased plasma sphingolipids and diacylglycerols, whereas EX reduced acylcarnitines. Plasma triacylglycerols and branched-chain amino acids were strongly correlated with liver fat, and triacylglycerols showed the strongest association with IMAT volume. Weight loss is more effective than endurance exercise training without weight loss for reducing IMAT and liver steatosis, with IMAT loss exceeding muscle loss. Plasma lipids and metabolites signatures are associated with liver fat and IMAT, supporting their potential utility as non-invasive biomarkers.